Turning Point Taps eFFECTOR’s Reich as Its Chief Scientific Officer

Precision oncology company Turning Point Therapeutics (NASDAQ: [[ticker:TPTX]]) on Thursday said it has appointed Siegfried Reich as executive vice president and chief scientific officer. Reich, whose new role starts March 2, was most recently senior vice president of research at another San Diego-based cancer drug developer, eFFECTOR Therapeutics, which he co-founded.

Reich’s experience includes time as a research fellow at the Eli Lilly (NYSE: [[ticker:LLY]]) biotech center in San Diego and leadership positions at SGX Pharmaceuticals (now part of Lilly), Pfizer (NYSE: [[ticker:PFE]]), and Agouron Pharmaceuticals (now part of Pfizer). He is the inventor of axitinib (Inlyta), a chemotherapy, and nelfinavir (Viracept), an HIV treatment.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo